Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 10/20 | 0.52 |
| ▸ | CCND1 | P24385 | 10/20 | 0.52 |
| ▸ | CDK2 | P24941 | 9/20 | 0.52 |
| ▸ | CCNE2 | O96020 | 8/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 8/20 | 0.52 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.46 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.46 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.46 |
| ▸ | COMT | P21964 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6749016 | 0.89 | CDK4 (0.58) | CDK4CCND1CDK2CCNE2CCNE1 | |
| SCHEMBL6753308 | 0.80 | CDK2 (0.69) | CDK4CCND1CDK2CCNE2CCNE1 | |
| SCHEMBL13010028 | 0.79 | CCNE2 (0.54) | CDK4CCND1CDK2CCNE2CCNE1 | |
| SCHEMBL25296388 | 0.75 | CDK2 (0.49) | CDK4CCND1CDK2CCNE2CCNE1 | |
| SCHEMBL29404936 | 0.75 | CDK2 (0.49) | CDK4CCND1CDK2CCNE2CCNE1 | |
| SCHEMBL7090159 | 0.73 | CDK4 (0.71) | CDK4CCND1CDK2CCNE2CCNE1 | |
| SCHEMBL6753304 | 0.73 | CDK4 (0.76) | CDK4CCND1CDK2CCNE2CCNE1 | |
| SCHEMBL6995067 | 0.70 | CDK4 (0.57) | CDK4CCND1CDK2CCNE2CCNE1 | |
| SCHEMBL7148608 | 0.70 | CDK4 (0.66) | CDK4CCND1CDK2CCNE2CCNE1 | |
| SCHEMBL9071199 | 0.70 | IDO1 (0.47) | CDK4CCND1ALDH1A1CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6706718-B2 | POTENT INHIBITORS OF CYCLIN DEPENDENT KINASES; TREATING CANCER OR OTHER PROLIFERATIVE DISEASES | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-16 | — | — | US | disclosed |
| US-6706718-B2 | POTENT INHIBITORS OF CYCLIN DEPENDENT KINASES; TREATING CANCER OR OTHER PROLIFERATIVE DISEASES | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-16 | — | — | US | disclosed |
| US-6706718-B2 | POTENT INHIBITORS OF CYCLIN DEPENDENT KINASES; TREATING CANCER OR OTHER PROLIFERATIVE DISEASES | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-16 | — | — | US | disclosed |
| WO-2002044174-A3 | 3-(2,4-DIMETHYLTHIAZOL-5-YL) INDENO[1,2-C]PYRAZOL-4-ONE DERIVATIVES AS CDK INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2003-01-23 | — | — | WO | disclosed |
| WO-2002044174-A3 | 3-(2,4-DIMETHYLTHIAZOL-5-YL) INDENO[1,2-C]PYRAZOL-4-ONE DERIVATIVES AS CDK INHIBITORS | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2003-01-23 | — | — | WO | disclosed |
| US-20020107274-A1 | 3- (2,4-dimethylthiazol-5-yl) indeno [1,2-c]pyrazol-4-one derivatives and their uses | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-08-08 | — | — | US | disclosed |
| US-20020107274-A1 | 3- (2,4-dimethylthiazol-5-yl) indeno [1,2-c]pyrazol-4-one derivatives and their uses | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-08-08 | — | — | US | disclosed |
| WO-2002044174-A2 | 3-(2,4-DIMETHYLTHIAZOL-5-YL) INDENO[1,2-C]PYRAZOL-4-ONE DERIVATIVES AS CDK INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-06-06 | — | — | WO | disclosed |
| WO-2002044174-A2 | 3-(2,4-DIMETHYLTHIAZOL-5-YL) INDENO[1,2-C]PYRAZOL-4-ONE DERIVATIVES AS CDK INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107274-A1 | 3- (2,4-dimethylthiazol-5-yl) indeno [1,2-c]pyrazol-4-one derivatives and their uses | CCNA1, CCNI, CDKN1A | CDK4 10/4885CCND1 34/4885CDK2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.